News/ News/ News/ Oncology/ R&D

Will new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?

, , , , 0 Comment

Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug